Skip to main content
Lipocine Inc. logo

Lipocine Inc. — Investor Relations & Filings

Ticker · LPCN ISIN · US53630X1046 LEI · 549300RXPEQXOJXVBI10 US Manufacturing
Open in API
Filings indexed 787 across all filing types
Latest filing 2015-06-17 Declaration of Voting R…
Country US United States of America
Listing US LPCN

About Lipocine Inc.

https://www.lipocine.com/

Lipocine Inc. is a clinical-stage biopharmaceutical company that develops treatments for metabolic, endocrine, and central nervous system disorders. The company leverages its proprietary Lip'ral drug delivery technology to enhance the oral absorption of water-insoluble drugs, aiming to improve patient compliance and therapeutic outcomes. Its portfolio includes TLANDO®, an FDA-approved oral testosterone replacement therapy. Lipocine's development pipeline features candidates for conditions such as non-alcoholic steatohepatitis (NASH), postpartum depression, obesity, and prevention of preterm birth. The company's strategy often involves using the 505(b)(2) regulatory pathway to develop improved formulations of established drugs.

Recent filings

Filing Released Lang Actions
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 17, 2015, reporting on the results of the company's Annual General Meeting (AGM) held on June 16, 2015. It details the voting results for the election of directors and the ratification of the appointment of the independent registered public accounting firm. The content focuses exclusively on the submission of matters to a vote of security holders, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements. The document length is 3317 characters, which is relatively short and consistent with a voting results announcement rather than a full report. Therefore, the appropriate classification is DVA (Declaration of Voting Results & Voting Rights Announcements).
2015-06-17 English
Director's Dealing 2015
Director's Dealing
2015-06-15 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce specific events or disclosures. The text indicates that the company issued a press release about the successful completion of a food effect study for a product candidate. The document is short (2317 characters) and primarily serves to announce this event and attach the press release. There are no financial statements or detailed financial data included. This fits the profile of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into more specific categories like Earnings Release or Annual Report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2015-06-15 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce specific events. The text indicates that the filing announces a press release about development plans for a product candidate, attached as an exhibit. There are no financial statements or detailed financial data included. The document is short (2279 characters) and primarily serves as an announcement of a press release rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2015-06-08 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce specific events or disclosures. The content includes a press release about an orphan drug designation for a product candidate, attached as an exhibit. There are no financial statements or detailed financial data presented. The document is short (2309 characters) and primarily serves as an announcement of a specific event rather than a full financial report or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2015-06-02 English
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 1, 2015, by Lipocine Inc. It specifically mentions an update to the company's corporate presentation used for investor meetings and attaches the updated presentation as Exhibit 99.1. The document does not contain financial statements or detailed financial analysis but rather provides an updated presentation for investors. According to the filing definitions, a corporate presentation for investors focusing on financials, strategy, and market position fits the category of Investor Presentation (IP). The document length is short (2203 characters), but it includes the presentation itself as an exhibit, not just an announcement of its availability, so it is not a Report Publication Announcement (RPA). Therefore, the correct classification is Investor Presentation (IP).
2015-06-01 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.